Catalonia shows its potential teamwork with the REVASCAT clinical trial in mechanical thrombectomy in grave ischemic stroke

21 May

Sònia AbilleiraSònia Abilleira Castells, neurologist. Plan for Cerebral Vascular Disease

A clinical trial conducted entirely in Catalonia with the participation of four tertiary stroke hospitals and the support of the master plan for cerebral vascular disease, showed that treatment with catheters in the acute phases of severe ischemic stroke is crucial for good clinical outcomes.

Ischemic stroke causes around 8,500 annual hospitalizations in Catalonia. An estimated 70% of patients are either dead or are in a situation of dependency within 5-years of the stroke. Until now, the only treatment available to us was a drug administered intravenously in the first 4.5 hours of the stroke achieving lysis or a rupture of the thrombus which for a percentage of the patients increased the likelihood of survival without significant neurological sequels. This treatment, known as intravenous thrombolysis has a very low efficiency when the thrombus is located on a main artery of the brain which happens in 25% of cases, translating clinically into more severe strokes. Continue reading